pmid	doi	year	title	Hugo_Symbol
31355228	10.21037/atm.2019.05.28	2022	Prognostic significance of the <i>PANK</i> family expression in acute myeloid leukemia.	MET
31576173	10.2147/CMAR.S194337	2022	Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.	MET
31749998	10.1136/bmjgh-2019-001825	2022	Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review.	MET
31807491	10.4103/sajc.sajc_373_18	2022	Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association.	MET
32346306	10.2147/IJGM.S245779	2022	Patterns of Glucose Fluctuation are Challenging in Patients Treated for Non-Hodgkin's Lymphoma.	MET
32408414	10.5045/br.2020.2020032	2022	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.	MET
32457620	10.3389/fphar.2020.00621	2022	Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System.	MET
32577090	10.6001/actamedica.v27i1.4260	2022	Improvement in childhood cancer survival in Lithuania over three decades.	MET
32606772	10.2147/OTT.S250233	2022	HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.	MET
32656132	10.4103/ajns.AJNS_366_19	2022	Radiologic-Histopathologic Correlation of Adult Spinal Tumors: A Retrospective Study.	MET
32661506	10.15344/2456-8007/2020/145	2022	Prevalence of Malignancy Among Urban Black Rheumatoid Arthritis Patients.	MET
33043062	10.36469/jheor.2020.17088	2022	Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.	MET
33094130	10.14338/IJPT-20-00010.1	2022	Reducing Heart Dose with Protons and Cardiac Substructure Sparing for Mediastinal Lymphoma Treatment.	MET
33145207	10.4103/ajns.AJNS_208_20	2022	Outcome and Prognostic Factors of Primary Central Nervous System Lymphoma in Southern Thailand.	MET
33402590	10.4103/ijc.IJC_470_19	2022	FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.	MET
33423957	10.1016/j.jasc.2020.12.002	2022	Oncogenic gene transcripts detection by FISH on liquid-based cytology slides of 338 advanced lung cancer patients.	MET
33487576	10.1016/j.clml.2020.12.015	2022	Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.	MET
33537137	10.1016/j.amsu.2021.01.059	2022	A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years.	MET
33632668	10.1016/j.clml.2020.12.012	2022	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	MET
33660798	10.26355/eurrev_202102_25083	2022	Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.	MET
33685866	10.1158/1078-0432.CCR-21-0032	2022	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer.	MET
33776456	10.2147/IDR.S295077	2022	The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma.	MET
33889527	10.21037/tlcr-21-160	2022	Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.	MET
33889528	10.21037/tlcr-20-1113	2022	A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations.	MET
33898318	10.3389/fonc.2021.647598	2022	Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.	MET
33951890	10.3324/haematol.2021.278311	2022	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.	MET
33952592	10.1136/jclinpath-2021-207597	2022	Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.	MET
33977256	10.1002/iju5.12279	2022	Rare case of immunoglobulin G4-related disease arising in gonadal glands with long-term remission without steroid treatment: Discussion and literature review.	MET
34003566	10.1002/pbc.29141	2022	Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.	MET
34011485	10.1016/j.clml.2021.04.003	2022	The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia.	MET
34031277	10.5045/br.2021.2021028	2022	Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma.	MET
34045224	10.1136/bmjspcare-2020-002532	2022	Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis.	MET
34052119	10.1016/j.oraloncology.2021.105351	2022	Solitary extramedullary plasmacytoma of the nasopharynx: The role of flow cytometry.	MET
34058070	10.1002/1878-0261.13033	2022	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	MET
34059475	10.1016/j.cllc.2021.04.008	2022	Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.	MET
34110383	10.1001/jamaoncol.2021.1649	2022	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.	MET
34137303	10.1177/00034894211025171	2022	Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival.	MET
34214988	10.3171/2020.12.JNS202517	2022	Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma.	MET
34274491	10.1016/j.jtct.2021.07.010	2022	A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma.	MET
34313176	10.1080/10428194.2021.1957868	2022	Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.	MET
34321836	10.21147/j.issn.1000-9604.2021.03.11	2022	Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.	MET
34326171	10.1136/jitc-2021-002968	2022	Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.	MET
34336635	10.3389/fonc.2021.609882	2022	Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis.	MET
34409369	10.1016/j.jdin.2021.01.002	2022	Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review.	MET
34410295	10.1001/jamaoncol.2021.2723	2022	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.	MET
34438277	10.1016/j.jchromb.2021.122905	2022	A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry.	MET
34464024	10.1111/vco.12768	2022	Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.	MET
34465277	10.2174/0929867328666210831142311	2022	The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy.	MET
34476905	10.1002/jmrs.540	2022	A scoping review of patient selection methods for proton therapy.	MET
34486541	10.1097/MPH.0000000000002301	2022	Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma.	MET
34490598	10.1007/s12185-021-03217-4	2022	A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.	MET
34541785	10.1111/jcmm.16897	2022	Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.	MET
34562212	10.1007/s11356-021-16616-1	2022	Physalis pubescens L. alleviates testicular disruptions associated with streptozotocin-induced diabetes in male Wistar rats, Rattus norvegicus.	MET
34587856	10.1080/10428194.2021.1984460	2022	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.	MET
34591804	10.1097/INF.0000000000003312	2022	Initial Seronegative West Nile Virus Encephalitis in an Immunocompromised Child.	MET
34595671	10.1007/s40273-021-01089-4	2022	Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.	MET
34599665	10.1007/s00520-021-06588-w	2022	Physical activity levels, exercise preferences, and exercise barriers in Korean children and adolescents after cancer treatment.	MET
34617607	10.1111/jsap.13438	2022	Diagnostic accuracy of ultrasonography to detect hepatic and splenic lymphomatous infiltration in dogs and cats.	MET
34632935	10.1080/10428194.2021.1986217	2022	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.	MET
34648216	10.1002/pbc.29387	2022	Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia.	MET
34651428	10.1111/jcmm.16953	2022	Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.	MET
34686712	10.1038/s41598-021-00309-3	2022	Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.	MET
34696815	10.1186/s40360-021-00529-3	2022	High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.	MET
34702929	10.1038/s41598-021-00746-0	2022	Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma.	MET
34757015	10.1016/j.jmoldx.2021.10.001	2022	Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR.	MET
34796780	10.1080/10408444.2021.1997911	2022	Using the Matrix to bridge the epidemiology/risk assessment gap: a case study of 2,4-D.	MET
34798339	10.1016/j.wneu.2021.11.042	2022	Contiguous Meningioma and B-Cell Lymphoma: A Scoping Review and Case Illustration.	MET
34805720	10.1177/2473974X211059081	2022	<sup>18</sup>FDG-PET/CT Specificity for the Detection of Lymphoma Recurrence in the Tonsils.	MET
34826411	10.1016/S2352-3026(21)00307-0	2022	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.	MET
34838280	10.1016/j.jval.2021.06.012	2022	Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov.	MET
34843129	10.1111/his.14603	2022	ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.	MET
34854541	10.1002/pbc.29437	2022	Prevalence of hearing screening failures in low-risk childhood cancer survivors.	MET
34862665	10.1111/ejh.13728	2022	Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma.	MET
34921238	10.1038/s41591-021-01622-0	2022	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.	MET
34980267	10.1186/s41043-021-00280-9	2022	Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis.	MET
34987411	10.3389/fphar.2021.809467	2022	Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report.	MET
34994987	10.1002/14651858.CD013453.pub2	2022	Targeted therapy for advanced anaplastic lymphoma kinase (&lt;I&gt;ALK&lt;/I&gt;)-rearranged non-small cell lung cancer.	MET
34999675		2022	A Study on Clinical Presentation and Histological Diagnosis of Lymphadenopathy Patients Admitted In Department of Medicine in A Tertiary Hospital.	MET
35003359	10.7150/jca.63003	2022	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.	MET
35007777	10.1016/j.tcam.2021.100622	2022	Retrospective Study of Canine Peripheral Lymphadenopathy in a Mediterranean Region: 130 Cases.	MET
35012520	10.1186/s12890-021-01803-0	2022	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.	MET
35017140		2022	Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report.	MET
35018520	10.1007/s00520-022-06818-9	2022	Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.	MET
35045791	10.1080/10428194.2021.2024817	2022	Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.	MET
35102119	10.1097/BRS.0000000000004327	2022	Patient Reported Outcomes in Metastatic Spine Disease: Concurrent Validity of PROMIS with the Spine Oncology Study Group Outcome Questionnaire.	MET
35116617	10.21037/tcr-20-3473	2022	Complex genetic alterations contribute to rapid disease progression in an <i>ALK</i> rearrangement lung adenocarcinoma patient: a case report.	MET
35116684	10.21037/tcr-21-642	2022	Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.	MET
35120432	10.1080/10428194.2021.2024818	2022	High-dose methotrexate dosing strategy in primary central nervous system lymphoma.	MET
35123117	10.1016/j.jtct.2022.01.024	2022	Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.	MET
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	MET
35125312	10.1016/j.iccn.2021.103187	2022	Symptom experiences of critically-ill hematologic malignancy patients: A scoping review.	MET
35133455	10.1007/s00404-022-06410-w	2022	Increased incidence of childhood lymphoma in children with a history of small for gestational age at birth.	MET
35133871	10.1200/JCO.21.01648	2022	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.	MET
35136485	10.18632/oncotarget.28189	2022	GZ17-6.02 and axitinib interact to kill renal carcinoma cells.	MET
35149250	10.1016/j.wneu.2022.02.015	2022	Computed Tomography Hounsfield Units as a Predictor of Reoperation and Graft Subsidence After Standalone and Multilevel Lateral Lumbar Interbody Fusion.	MET
35171109	10.2196/32826	2022	Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale.	MET
35182296	10.1007/s11864-021-00925-1	2022	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.	MET
35184940	10.1016/j.semcdb.2022.02.007	2022	Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer.	MET
35198656	10.1016/j.ejro.2022.100400	2022	Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis.	MET
35198835	10.1016/j.adro.2021.100888	2022	Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials.	MET
35209723	10.1177/03000605221080875	2022	Characteristics and surgical outcomes of patients with atraumatic splenic rupture.	MET
35218999	10.1016/j.jtct.2022.02.017	2022	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma.	MET
35233056	10.1038/s41698-022-00256-w	2022	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.	MET
35240075	10.1016/S2352-3026(22)00034-5	2022	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.	MET
35241295	10.1016/j.clinthera.2022.02.004	2022	Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.	MET
35241462	10.1136/bmjopen-2020-041961	2022	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.	MET
35256158	10.1016/j.bulcan.2022.01.011	2022	[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]	MET
35282507	10.7759/cureus.21959	2022	Fever of Unknown Origin: The Workup and Diagnosis of Pel-Ebstein Fever.	MET
35288347	10.1016/j.jtct.2022.03.006	2022	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.	MET
35307610	10.1016/j.clim.2022.108982	2022	What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review.	MET
35309168	10.1155/2022/5687832	2022	Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.	MET
35311939	10.1093/ajcp/aqac030	2022	Primary Pancreatic Lymphoma Evaluated by Fine-Needle Aspiration.	MET
35314842	10.1038/s41591-022-01731-4	2022	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.	MET
35319677	10.4067/S0034-98872021000901249	2022	[Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia].	MET
35322575	10.1002/cam4.4686	2022	Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.	MET
35358350	10.1002/ajh.26552	2022	First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.	MET
35372013	10.3389/fonc.2022.853076	2022	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016).	MET
35373599	10.1177/00034894221088175	2022	Epidemiology and Prognostic Indicators of Survival in Tongue Lymphoma.	MET
35392482	10.1097/HS9.0000000000000707	2022	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations.	MET
35393251	10.1016/j.clml.2022.02.002	2022	Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study.	MET
35395124	10.1111/vop.12988	2022	Retrospective evaluation of canine primary, multicentric, and metastatic intraocular neoplasia.	MET
35395987	10.19746/j.cnki.issn.1009-2137.2022.02.030	2022	[Changes of Serum Complement C1q in Patients with Multiple Myeloma].	MET
35399482	10.7759/cureus.22935	2022	Radiological Findings on Chest Computed Tomography in Patients With the Primary Diagnosed Chronic Lymphoproliferative Diseases.	MET
35406482	10.3390/cancers14071711	2022	Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.	MET
35426613	10.1007/s00432-022-04022-0	2022	Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.	MET
35430374	10.1016/j.jmoldx.2022.03.006	2022	Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.	MET
35445764	10.1111/cup.14243	2022	Application of the current diagnostic algorithm for early mycosis fungoides to a single center cohort: Identification of challenges and suggestions for modification.	MET
35468269	10.4143/crt.2022.008	2022	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts.	MET
35468945	10.1038/s41375-022-01576-3	2022	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.	MET
35471999	10.1371/journal.pone.0266623	2022	Clinical validation of a next-generation sequencing-based multi-cancer early detection liquid biopsy blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study.	MET
35485864	10.1097/RLU.0000000000004238	2022	First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.	MET
35485962	10.1111/ijd.16224	2022	Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.	MET
35491131	10.2169/internalmedicine.9300-21	2022	Eosinophilic Fasciitis with Hypereosinophilia as the Initial Clinical Manifestation of Peripheral T-Cell Lymphoma, Not Otherwise Specified.	MET
35491468	10.1111/vco.12825	2022	Using digital RNA counting to establish flow cytometry diagnostic criteria for subtypes of CD34+ canine acute leukaemia.	MET
35506104	10.1002/pul2.12047	2022	Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation.	MET
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.	MET
35512080	10.1097/MD.0000000000029219	2022	Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma: A case report and literature review.	MET
35521776	10.1530/ETJ-21-0144	2022	Clinical differences between IgG4 Hashimoto's thyroiditis and primary thyroid lymphoma.	MET
35526853	10.1134/S0006297922030063	2022	Preparative Production and Purification of Recombinant Human Cyclophilin A.	MET
35527361	10.1002/cam4.4797	2022	Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States.	MET
35534379	10.1016/j.clml.2022.04.009	2022	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.	MET
35552415	10.1038/s41540-022-00225-w	2022	Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.	MET
35560808	10.1111/1759-7714.14455	2022	Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.	MET
35571080	10.3389/fphar.2022.875016	2022	Anticancer Activities of <i>Polygonum odoratum</i> Lour.: A Systematic Review.	MET
35593342	10.2174/1389557522666220519085134	2022	Advances and Challenges in the Investigation of Metastasis in Diffuse Large B-Cell Lymphoma.	MET
35626685	10.3390/cells11101648	2022	SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta.	MET
35669427	10.3389/fonc.2022.873111	2022	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma.	MET
35670252	10.1002/pon.5973	2022	Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.	MET
35674661	10.1158/1078-0432.CCR-21-3648	2022	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.	MET
35688904	10.1007/s00277-022-04876-x	2022	Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.	MET
35731278	10.1007/s00277-022-04889-6	2022	Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.	MET
35739536	10.1186/s12920-022-01291-z	2022	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	MET
35741139	10.3390/diagnostics12061330	2022	Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.	MET
35748237	10.2217/pme-2021-0059	2022	Targeting molecular alterations in non-small-cell lung cancer: what's next?	MET
35760768	10.1002/cnr2.1661	2022	A longitudinal analysis of early lung function trajectory in survivors of childhood Hodgkin lymphoma.	MET
35772168	10.1182/bloodadvances.2022007011	2022	Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.	MET
35772506	10.1016/j.toxicon.2022.06.010	2022	Antitumor effects of oleandrin in different types of cancers: Systematic review.	MET
35786067	10.1177/10781552221110470	2022	Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience.	MET
35788019	10.2196/38722	2022	Improving Clinical and Family Communication for Adult Child Caregivers of a Parent With a Blood Cancer: Single-Arm Pre-Post Pilot Intervention.	MET
35814853	10.1016/j.adro.2022.100940	2022	Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence.	MET
35839058	10.1097/MD.0000000000029750	2022	Predictors of in-hospital mortality in a cohort of people living with HIV (PLHIV) admitted to an academic medical intensive care unit from 2009 to 2014: A retrospective cohort study.	MET
35839452	10.1182/blood.2022015478	2022	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.	MET
35839786	10.1016/S1470-2045(22)00339-4	2022	Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.	MET
35841268	10.1111/cup.14293	2022	Primary cutaneous gamma-delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: Clues to the diagnosis.	MET
35842643	10.1186/s13045-022-01316-1	2022	Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.	MET
35851959	10.1111/trf.17030	2022	Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.	MET
35858181	10.1002/hon.3054	2022	Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.	MET
35867960	10.1200/JCO.21.01281	2022	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.	MET
35869162	10.1007/s00467-022-05692-1	2022	Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure.	MET
35872785	10.3389/fmed.2022.906364	2022	Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer.	MET
35896160	10.1111/1759-7714.14592	2022	Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.	MET
35900560	10.4103/jcrt.JCRT_559_20	2022	Primary pulmonary epithelial-myoepithelial carcinoma: Report of a rare and under-diagnosed low-grade malignancy.	MET
35907041	10.1007/s00412-022-00775-2	2022	The spectrum of chromosomal translocations in the Arab world: ethnic-specific chromosomal translocations and their relevance to diseases.	MET
35932329	10.1007/s00259-022-05918-2	2022	The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.	MET
35937394	10.1155/2022/8802469	2022	Cognition/Psychological Burden and Resilience in Cutaneous T-Cell Lymphoma and Psoriasis Patients: Real-Life Data and Implications for the Treatment.	MET
35950895	10.1111/cas.15529	2022	Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.	MET
35970303	10.1016/j.jtct.2022.08.011	2022	Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.	MET
35973192	10.1182/bloodadvances.2022008150	2022	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.	MET
36002199	10.3779/j.issn.1009-3419.2022.102.23	2022	[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].	MET
36013165	10.3390/jcm11164928	2022	Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.	MET
36030394	10.1111/ejh.13854	2022	The Safety of Bruton's Tyrosine Kinase Inhibitors in B-cell Malignancies: A Systematic Review.	MET
36056778	10.1111/ejh.13859	2022	JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO).	MET
36067076	10.1089/jayao.2022.0062	2022	Pre-Treatment Left Ventricular Ejection Fraction Assessment and Long-Term Cardiovascular Outcomes in Adolescent and Young Adult Lymphoma Survivors.	MET
36072511	10.2147/OTT.S382722	2022	Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis.	MET
30724750	10.1097/PAI.0000000000000730	2021	Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET.	MET
31177400	10.1007/s10637-019-00802-7	2021	Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.	MET
31297240	10.1136/esmoopen-2019-000498	2021	Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.	MET
31393251	10.2174/1570163816666190808120843	2021	Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.	MET
31537164	10.1177/1098612X19873197	2021	Ultrasonographic honeycomb pattern of the spleen in cats: correlation with pathological diagnosis in 33 cases.	MET
31560977	10.1016/j.jaad.2019.09.032	2021	Pyoderma gangrenosum in hematologic malignancies: A systematic review.	MET
31598903	10.1007/s12094-019-02218-4	2021	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	MET
31640446	10.1080/10428194.2019.1680841	2021	Pediatric hodgkin lymphoma: disparities in survival by race.	MET
31652963	10.3390/jcm8111772	2021	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.	MET
31693288	10.1111/vop.12717	2021	Evaluation of cytology and histopathology for the diagnosis of canine orbital neoplasia: 112 cases (2004-2019) and review of the literature.	MET
31749202	10.1111/head.13690	2021	Great Auricular Neuralgia: Case Series.	MET
31780415	10.1016/j.clml.2019.09.622	2021	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.	MET
31839532	10.1016/j.cllc.2019.11.006	2021	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.	MET
31897734	10.1007/s00795-019-00241-6	2021	Clinicopathologic analysis of gastric mucosa-associated lymphoid tissue lymphoma with or without c-Met expression.	MET
31917616	10.1080/17476348.2020.1714441	2021	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.	MET
31983636	10.1016/j.clml.2019.10.019	2021	Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.	MET
31992504	10.1016/j.clml.2019.12.011	2021	Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience.	MET
32008116	10.1007/s00296-020-04522-7	2021	Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome.	MET
32028325	10.1097/QAD.0000000000002491	2021	Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients.	MET
32041944	10.1038/s41419-020-2307-5	2021	Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.	MET
32077838	10.2174/2589977512666200220122650	2021	Gene Expression and Resistance to Glucocorticoid-Induced Apoptosis in Acute Lymphoblastic Leukemia: A Brief Review and Update.	MET
32077984	10.1007/s00234-020-02377-0	2021	Atypical radiological findings of primary central nervous system lymphoma.	MET
32086345	10.1158/1078-0432.CCR-19-3906	2021	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.	MET
32088367	10.1016/j.bbmt.2020.02.009	2021	A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.	MET
32126881	10.1080/10799893.2020.1735418	2021	Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening.	MET
32132106	10.1136/esmoopen-2019-000626	2021	Genomic-guided precision therapy for soft tissue sarcoma.	MET
32165081	10.1016/j.jdermsci.2020.01.013	2021	The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.	MET
32165325	10.1016/j.bbmt.2020.02.026	2021	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?	MET
32167380	10.5858/arpa.2019-0580-OA	2021	Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue.	MET
32192977	10.1016/j.clml.2019.12.015	2021	Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry.	MET
32229035	10.1016/j.annder.2020.02.007	2021	[Clinical heterogeneity of poikilodermatous mycosis fungoides: A retrospective study of 12 cases].	MET
32229347	10.1016/j.bioorg.2020.103778	2021	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.	MET
32236526	10.1182/bloodadvances.2019000638	2021	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.	MET
32236987	10.1111/jdv.16397	2021	Pigmented purpuric dermatosis in children: a retrospective cohort with emphasis on treatment and outcomes.	MET
32284620	10.5507/bp.2020.015	2021	Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.	MET
32289463	10.1016/j.clim.2020.108419	2021	Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.	MET
32297447	10.1634/theoncologist.2019-0559	2021	Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.	MET
32303134	10.14735/amko2020138	2021	Invasive Rhino-Orbito-Cerebral Mucormycosis in Pediatric Patient with Acute Leukemia.	MET
32325490	10.1182/blood.2020005288	2021	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.	MET
32340914	10.1016/j.clml.2020.02.019	2021	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study.	MET
32354424	10.1016/j.crad.2020.03.037	2021	Clinical and imaging features in adult patients with bone marrow haemophagocytosis with and without haemophagocytic lymphohistiocytosis: a single-institution experience.	MET
32363427	10.1007/s10637-020-00925-2	2021	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.	MET
32365229	10.1002/cncr.32876	2021	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.	MET
32398031	10.1186/s12885-020-06891-5	2021	Cancer incidence attributable to tuberculosis in 2015: global, regional, and national estimates.	MET
32401634	10.1200/JCO.19.02104	2021	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.	MET
32413196	10.1111/vop.12776	2021	Evaluation of cytology and histopathology for the diagnosis of feline orbital neoplasia: 81 cases (2004-2019) and review of the literature.	MET
32429639	10.3779/j.issn.1009-3419.2020.101.04	2021	[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].	MET
32450595	10.1055/s-0039-1700994	2021	Targeted Therapy for Non-Small Cell Lung Cancer.	MET
32452714	10.1080/10428194.2020.1768388	2021	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.	MET
32472430	10.1007/s12325-020-01392-0	2021	Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.	MET
32473105	10.1016/j.hemonc.2020.05.002	2021	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis.	MET
32484895	10.3928/23258160-20200108-01	2021	Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma.	MET
32506523	10.1002/gcc.22877	2021	Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern.	MET
32519904	10.1080/10428194.2020.1772478	2021	Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma.	MET
32521388	10.1016/j.lungcan.2020.05.018	2021	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.	MET
32528460	10.3389/fimmu.2020.00482	2021	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.	MET
32558492	10.1615/CritRevEukaryotGeneExpr.2020033468	2021	MTHFR-C677T Gene Polymorphism and Susceptibility to Acute Lymphoblastic Leukemia in Children: A Meta-Analysis.	MET
32605899	10.1016/j.clml.2020.05.009	2021	A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity.	MET
32606424	10.1038/s41408-020-0337-y	2021	B-cell maturation antigen expression across hematologic cancers: a systematic literature review.	MET
32622001	10.1016/j.jormas.2020.06.012	2021	A systematic approach on the frequency of cleft lip/palate in pediatric patients with leukemia.	MET
32624445	10.1016/j.clml.2020.05.019	2021	Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.	MET
32638051	10.1007/s00247-020-04752-8	2021	Solitary long-bone epiphyseal lesions in children: radiologic-pathological correlation and epidemiology.	MET
32646834	10.1016/j.clml.2020.04.006	2021	The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab.	MET
32650968	10.1016/j.patol.2019.11.004	2021	[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].	MET
32657049	10.1002/mgg3.1398	2021	Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua.	MET
32661116	10.1136/jitc-2020-000734	2021	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.	MET
32662694	10.1080/10428194.2020.1789622	2021	Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant.	MET
32666499	10.1007/s11605-020-04730-3	2021	Surgical Management of Small Bowel Lymphoma.	MET
32686009	10.1007/s10689-020-00196-z	2021	Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene.	MET
32720195	10.1007/s11065-020-09446-4	2021	Assessment of Executive Functions after Treatment of Childhood Acute Lymphoid Leukemia: a Systematic Review.	MET
32730187	10.1200/JCO.20.00157	2021	Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.	MET
32747750	10.1038/s41388-020-01393-x	2021	Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma.	MET
32748464	10.1002/hed.26381	2021	Core needle biopsy for diagnosing lymphoma in cervical lymphadenopathy: Meta-analysis.	MET
32763229	10.1016/j.hemonc.2020.07.007	2021	Molecular events and cytotoxic effects of a novel thiosemicarbazone derivative in human leukemia and lymphoma cell lines.	MET
32768316	10.1016/j.clnu.2020.07.023	2021	Sarcopenia predicts overall survival in patients with malignant hematological diseases: A meta-analysis.	MET
32799209	10.1159/000509159	2021	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.	MET
32807027	10.1177/0049475520947907	2021	Aetiology of pyrexia of unknown origin in north India.	MET
32829325	10.1159/000509639	2021	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.	MET
32835902	10.1016/j.msard.2020.102451	2021	Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events.	MET
32838487	10.3779/j.issn.1009-3419.2020.102.14	2021	[Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].	MET
32860335	10.1002/cam4.3420	2021	Maintenance rituximab in Veterans with follicular lymphoma.	MET
32866816	10.1016/j.jns.2020.117102	2021	Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.	MET
32886757	10.5858/arpa.2019-0493-CP	2021	Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.	MET
32894957	10.14735/amko2020280	2021	Gamma-heavy chain disease.	MET
32909665	10.1002/pbc.28360	2021	Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.	MET
32924727	10.1089/jayao.2020.0090	2021	Contributing Factors of Unmet Needs Among Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia with Comorbidities.	MET
32947231	10.1016/j.anndiagpath.2020.151623	2021	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms.	MET
32949754	10.1016/j.bbmt.2020.09.004	2021	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.	MET
32960838	10.1097/CM9.0000000000001074	2021	Diffusion kurtosis imaging: correlation analysis of quantitative model parameters with molecular features in advanced lung adenocarcinoma.	MET
32967920	10.1136/esmoopen-2020-000977	2021	Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.	MET
32992346	10.1055/a-1252-2476	2021	DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study.	MET
33023529	10.1186/s12885-020-07431-x	2021	The relationship between physical activity and lymphoma: a systematic review and meta analysis.	MET
33026424	10.1001/jamasurg.2020.4124	2021	Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence.	MET
33037033	10.1136/esmoopen-2020-000858	2021	Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.	MET
33081486	10.1177/0284185120966710	2021	PET findings in lymphomatosis and gliomatosis of the brain: a comparison of C-11 methionine PET/CT and F-18 FDG PET/CT.	MET
33119210	10.1002/cncy.22380	2021	Expanding the utility of cytology preparations in cancer biomarker testing.	MET
33148004	10.1142/S0192415X20500810	2021	Bufalin: A Systematic Review of Research Hotspots and Antitumor Mechanisms by Text Mining and Bioinformatics.	MET
33162801	10.7150/ijms.51329	2021	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis.	MET
33165035	10.1097/CORR.0000000000001525	2021	Do Cohabitants Reliably Complete Questionnaires for Patients in a Terminal Cancer Stage when Assessing Quality of Life, Pain, Depression, and Anxiety?	MET
33208972	10.1038/d41586-020-03150-2	2021	Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer.	MET
33215340	10.1007/s11060-020-03597-3	2021	The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.	MET
33230098	10.1038/s41408-020-00388-x	2021	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.	MET
33244736	10.1007/s12325-020-01567-9	2021	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.	MET
33273183	10.1097/QAD.0000000000002692	2021	Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders.	MET
33299299	10.2147/DDDT.S274018	2021	Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.	MET
33307239	10.1016/j.jogoh.2020.102035	2021	Evaluation of ovarian reserve before and after chemotherapy.	MET
33336724	10.26355/eurrev_202012_23995	2021	MiR-150 inhibits proliferation of mantle-cell lymphoma cells via regulation of MET.	MET
33340237	10.1111/febs.15675	2021	Pharmacological preconditioning protects from ischemia/reperfusion-induced apoptosis by modulating Bcl-xL expression through a ROS-dependent mechanism.	MET
33382529	10.1002/cam4.3686	2021	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.	MET
33387041	10.1007/s00432-020-03476-4	2021	Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.	MET
33417474	10.1200/JCO.20.02477	2021	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.	MET
33418509	10.1016/j.ebiom.2020.103191	2021	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling.	MET
33444186	10.1136/bmjopen-2020-038605	2021	Routes to diagnosis of symptomatic cancer in sub-Saharan Africa: systematic review.	MET
33455071	10.1111/ijlh.13467	2021	The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.	MET
33470536	10.1111/1759-7714.13825	2021	Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.	MET
33472202	10.1159/000512933	2021	Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients.	MET
33475256	10.1111/1759-7714.13829	2021	Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report.	MET
33483528	10.1038/s41598-020-80724-0	2021	High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.	MET
33494549	10.3390/ph14020080	2021	Therapeutic Sequencing in ALK<sup>+</sup> NSCLC.	MET
33494630	10.1080/10428194.2020.1864351	2021	Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension.	MET
33495574	10.1038/s41374-021-00536-2	2021	An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.	MET
33496731	10.1182/bloodadvances.2020003213	2021	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.	MET
33501773	10.1002/pbc.28907	2021	Parental decision making regarding consent to randomization on Children's Oncology Group AALL0932.	MET
33501843	10.1177/0003489421990149	2021	Vocal Fold Motion Impairment Following Chemotherapy Administration: Case Reports and Review of the Literature.	MET
33503323	10.1002/cam4.3736	2021	Associations between race and survival in pediatric patients with diffuse large B-cell lymphoma.	MET
33512257	10.1089/jayao.2020.0154	2021	Increased Toxicity Among Adolescents and Young Adults Compared with Children Hospitalized with Acute Lymphoblastic Leukemia at Children's Hospitals in the United States.	MET
33513372	10.1016/S2352-3026(20)30366-5	2021	MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.	MET
33527553	10.1111/ejh.13591	2021	High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.	MET
33544247	10.1007/s00520-021-06035-w	2021	Feasibility and suitability of a graded exercise test in patients with aggressive hemato-oncological disease.	MET
33552685	10.1080/2162402X.2020.1865653	2021	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.	MET
33591324	10.1182/bloodadvances.2020002567	2021	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.	MET
33591844	10.1200/JCO.20.03570	2021	Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.	MET
33593440	10.1186/s40164-021-00208-3	2021	Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.	MET
33605187	10.1177/1098612X21994396	2021	Comparison of CT features of 79 cats with intranasal mass lesions.	MET
33621109	10.1200/JCO.20.01366	2021	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.	MET
33643753	10.7759/cureus.13333	2021	Trends in Childhood Cancer in Kuwait: Data From the 2004-2017 Registry.	MET
33671873	10.3390/cancers13040804	2021	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.	MET
33691381	10.3324/haematol.2020.267914	2021	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective.	MET
33694088	10.1007/s00520-021-06120-0	2021	High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.	MET
33722699	10.1016/j.critrevonc.2021.103299	2021	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.	MET
33751616	10.1111/vcp.12962	2021	Hematologic and clinical characteristics of dogs with circulating macrophage-like cells.	MET
33774076	10.1016/j.ijrobp.2021.03.035	2021	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria.	MET
33774128	10.1016/j.jpainsymman.2021.03.014	2021	Outcomes of Specialty Palliative Care Interventions for Patients With Hematologic Malignancies: A Systematic Review.	MET
33785333	10.1016/j.lfs.2021.119429	2021	Concerted outcome of metformin and low dose of radiation in modulation of cisplatin induced uremic encephalopathy via renal and neural preservation.	MET
33787818	10.1001/jamadermatol.2021.0345	2021	Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.	MET
33793828	10.1093/jpp/rgaa018	2021	Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.	MET
33807876	10.3390/ijms22052625	2021	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.	MET
33810911	10.1016/j.currproblcancer.2021.100739	2021	Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.	MET
33836877	10.1016/j.jtct.2021.01.007	2021	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas.	MET
33852456	10.1097/COC.0000000000000819	2021	Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.	MET
33855613	10.1007/s00383-021-04900-7	2021	Surgical management of unilateral oophorectomy for ovarian tissue cryopreservation in high-risk children and adolescents with varied backgrounds.	MET
33905264	10.1200/JCO.20.03502	2021	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.	MET
33918801	10.3390/cancers13081803	2021	Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States.	MET
33921066	10.3390/cancers13081909	2021	Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells.	MET
33959476	10.5306/wjco.v12.i4.217	2021	Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.	MET
34006913	10.1038/s41598-021-90046-4	2021	Analysis of the occurrence of hemophagocytic lymphohistiocytosis (HLH) features in patients with sepsis: a prospective study.	MET
34048168	10.31557/APJCP.2021.22.5.1407	2021	Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.	MET
34066104	10.3390/cancers13102337	2021	Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results.	MET
34070784	10.3390/jcm10112429	2021	Paracetamol Intake and Hematologic Malignancies: A Meta-Analysis of Observational Studies.	MET
34080380		2021	[Targeted therapies for non-small cell lung cancer : state of the art in 2021].	MET
34086170	10.1007/s10549-021-06258-9	2021	Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.	MET
34117602	10.1007/s40487-021-00155-3	2021	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.	MET
34127734	10.1038/s41598-021-92018-0	2021	Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.	MET
34149231	10.1055/s-0041-1726569	2021	Histomorphological and Morphometric Evaluation of Microvessel Density in Nodal Non-Hodgkin Lymphoma Using CD34 and CD105.	MET
34154602	10.1186/s12967-021-02925-z	2021	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.	MET
34176717	10.1016/j.jiac.2021.06.009	2021	Determination of reactivation rate and risk factors for Hepatitis B virus reactivation in low-positive cases: A retrospective cohort study.	MET
34190207	10.1097/NRL.0000000000000328	2021	Is Autologous Stem Cell Transplantation a Safe and Effective Alternative to Whole Brain Radiation as Consolidation Therapy in Patients With Primary Central Nervous System Lymphoma?: A Critically Appraised Topic.	MET
34190901	10.17843/rpmesp.2021.381.5488	2021	Listeria bacteremia in patients from a peruvian oncologic institute, 2005-2015.	MET
34191157	10.1186/s41824-020-00083-x	2021	Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study.	MET
34234236	10.1038/s41598-021-93484-2	2021	SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.	MET
34268436	10.21037/atm-20-6162	2021	Applications of artificial intelligence in oncologic <sup>18</sup>F-FDG PET/CT imaging: a systematic review.	MET
34312556	10.1038/s41591-021-01436-0	2021	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.	MET
34314938	10.1016/j.bmc.2021.116275	2021	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	MET
34319586	10.1002/ijc.33754	2021	A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.	MET
34343999	10.1159/000514821	2021	Multigene Combined Detection by RT-qPCR Using Cytological Specimens.	MET
34353680	10.1016/j.lungcan.2021.06.002	2021	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.	MET
34362156	10.3390/jcm10153374	2021	Patients with Persistent Polyclonal B-Cell Lymphocytosis Share the Symptomatic Criteria of Systemic Exertion Intolerance Disease.	MET
34362488	10.19746/j.cnki.issn.1009-2137.2021.04.013	2021	[Second-generation Sequencing Analysis of Ph<sup>+</sup> and Ph-like Childhood T-cell Acute Lymphoblastic Leukemia].	MET
34364036	10.1016/j.saa.2021.120216	2021	SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy.	MET
34378095	10.1007/s00277-021-04623-8	2021	Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.	MET
34392186	10.1016/j.ejca.2021.06.043	2021	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.	MET
34453768	10.1111/tid.13719	2021	Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.	MET
34464973	10.1182/bloodadvances.2021004779	2021	A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.	MET
34503286	10.3390/cancers13174476	2021	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.	MET
34534514	10.1016/S1470-2045(21)00455-1	2021	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.	MET
34572031	10.3390/cells10092382	2021	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity.	MET
34597375	10.1182/bloodadvances.2021005150	2021	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial.	MET
34598154	10.3171/2021.4.SPINE21344	2021	Perineural spread of peripheral neurolymphomatosis to the cauda equina.	MET
34613477	10.1007/s00508-021-01948-2	2021	CAR T-cell therapy and critical care : A survival guide for medical emergency teams.	MET
34618601	10.1200/JCO.21.00807	2021	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.	MET
34638496	10.3390/cancers13195012	2021	Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL).	MET
34642489	10.1038/s41591-021-01497-1	2021	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.	MET
34659965	10.7759/cureus.17752	2021	Hemophagocytic Lymphohistiocytosis Induced by Epstein-Barr Virus Infection and Newly Diagnosed Hodgkin Lymphoma.	MET
34729049	10.4103/jcar.jcar_14_21	2021	Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India.	MET
34781653		2021	Fever of Unknown Origin in Older Adults: A Prospective Observational Study from North India.	MET
34789083	10.1080/16078454.2021.1997414	2021	Diagnostic concordance of pathological methods and reports of hematopathologists compared to local nonspecialized pathologists in the diagnosis of lymphoma in Mexico.	MET
34796352	10.5187/jast.2021.e93	2021	Enhanced supply of methionine regulates protein synthesis in bovine mammary epithelial cells under hyperthermia condition.	MET
34861884	10.1186/s13044-021-00117-x	2021	Is Hashimoto thyroiditis associated with increasing risk of thyroid malignancies? A systematic review and meta-analysis.	MET
30940295	10.3727/096504019X15509372008132	2020	Different Types of <i>ROS1</i> Fusion Partners Yield Comparable Efficacy to Crizotinib.	MET
30941038	10.3389/fphar.2019.00247	2020	Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.	MET
30948292	10.1016/j.tmrv.2019.01.005	2020	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.	MET
30976989	10.1007/s11523-019-00636-6	2020	Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.	MET
31045506	10.2196/12453	2020	Effective Information Provision About the Side Effects of Treatment for Malignant Lymphoma: Protocol of a Randomized Controlled Trial Using Video Vignettes.	MET
31053975	10.1007/s10620-019-05629-z	2020	Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps.	MET
31060991	10.1016/j.clml.2019.04.003	2020	Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.	MET
31063012	10.5858/arpa.2018-0483-OA	2020	Cytologic Evaluation of Positron Emission Tomography-Computed Tomography-Positive Lymph Nodes Sampled by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Experience at a Large Cancer Center.	MET
31072955	10.1136/jnnp-2018-318957	2020	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS.	MET
31122976	10.1136/bmjopen-2018-026505	2020	Patients' decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study.	MET
31126146	10.3390/cells8050498	2020	c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.	MET
31127319	10.1007/s00280-019-03861-y	2020	Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.	MET
31166030	10.1111/ejh.13269	2020	FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?	MET
31201134	10.1016/j.clml.2019.05.001	2020	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.	MET
31219187	10.1002/jcp.28959	2020	Elucidation of the mechanism underlying CD44v6-induced transformation of IEC-6 normal intestinal epithelial cells.	MET
31242043	10.1200/CCI.19.00002	2020	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.	MET
31259825	10.1097/MPH.0000000000001534	2020	The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD.	MET
31274040	10.1080/10428194.2019.1630618	2020	Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.	MET
31278140	10.1242/bio.044362	2020	The effects of crizotinib in a transgenic <i>Drosophila</i> model expressing the human TPM4-ALK fusion gene or TPM4.	MET
31300873	10.1007/s00520-019-04983-y	2020	Exercise on quality of life and cancer-related fatigue for lymphoma survivors: a systematic review and meta-analysis.	MET
31305266	10.1097/PAS.0000000000001324	2020	Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With Hodgkin/Reed-Sternberg-like Cells of NK Phenotype.	MET
31307533	10.1186/s40425-019-0657-2	2020	Transgenerational transfer of gene-modified T cells.	MET
31307938	10.1016/j.cllc.2019.06.021	2020	Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.	MET
31315113	10.1159/000500666	2020	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.	MET
31338678	10.1007/s11010-019-03588-7	2020	Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.	MET
31347793	10.1002/pbc.27938	2020	Second malignancies in patients treated for Ewing sarcoma: A systematic review.	MET
31359183	10.1007/s00520-019-05006-6	2020	Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.	MET
31374369	10.1016/j.jtho.2019.07.017	2020	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.	MET
31388026	10.1038/s41598-019-46825-1	2020	Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.	MET
31396241	10.3389/fimmu.2019.01757	2020	From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies.	MET
31412611	10.3390/ijms20163939	2020	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (<i>ALK</i>) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.	MET
31441943	10.1002/cncr.32464	2020	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.	MET
31443309	10.3390/medicina55080490	2020	Malignant Pleural Effusion and Its Current Management: A Review.	MET
31443496	10.3390/cancers11091229	2020	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	MET
31448055	10.18632/oncotarget.27122	2020	Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome.	MET
31452405	10.1080/1744666X.2019.1658523	2020	Malignancy in common variable immunodeficiency: a systematic review and meta-analysis.	MET
31472421	10.1016/j.vhri.2019.04.008	2020	Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View.	MET
31520441	10.1111/myc.13001	2020	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.	MET
31522038	10.1016/j.leukres.2019.106222	2020	Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature.	MET
31529525	10.1111/jcpt.13007	2020	In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.	MET
31530473	10.1016/j.clml.2019.08.001	2020	Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center.	MET
31549264	10.1007/s10120-019-01008-9	2020	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.	MET
31554817	10.1038/s41467-019-12187-5	2020	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.	MET
31565620	10.7759/cureus.5217	2020	CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.	MET
31583605	10.1007/s40261-019-00859-5	2020	A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.	MET
31584608	10.1093/annonc/mdz407	2020	Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.	MET
31591840	10.3988/jcn.2019.15.4.511	2020	Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism.	MET
31599334	10.1007/s00134-019-05789-6	2020	Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies.	MET
31609151	10.1080/10428194.2019.1581930	2020	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.	MET
31611441	10.4103/IJPM.IJPM_69_19	2020	Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma.	MET
31639374	10.1016/j.taap.2019.114768	2020	ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway.	MET
31648940	10.1016/S1473-3099(19)30402-5	2020	Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies.	MET
31679027	10.1093/jas/skz339	2020	Dietary supplementation with free methionine or methionine dipeptide improves environment intestinal of broilers challenged with Eimeria spp.	MET
31681578	10.3389/fonc.2019.01040	2020	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.	MET
31711449	10.1186/s12890-019-0964-x	2020	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.	MET
31714642	10.1111/jocs.14337	2020	Surgical pericardial drainage procedures have a limited diagnostic sensitivity.	MET
31717403	10.3390/ijms20225590	2020	Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.	MET
31735071	10.1177/0960327119888277	2020	A review on the cardioprotective mechanisms of metformin against doxorubicin.	MET
31736189	10.1002/pds.4912	2020	Identifying monoclonal gammopathy of undetermined significance in electronic health data.	MET
31737634	10.3389/fmed.2019.00233	2020	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.	MET
31741249	10.1007/s11764-019-00823-4	2020	Blood cancer survivorship in NCI-Designated Cancer Centers: a study of services, gaps, and access barriers.	MET
31756212	10.1371/journal.pone.0225211	2020	Contrast-enhanced computed tomography findings of canine primary renal tumors including renal cell carcinoma, lymphoma, and hemangiosarcoma.	MET
31778074	10.2217/fon-2019-0653	2020	Dose-escalation trial of the ALK, MET &amp; ROS1 inhibitor, crizotinib, in patients with advanced cancer.	MET
31818895	10.1136/bcr-2019-232576	2020	Visceral leishmaniasis presenting as haemophagocytic lymphohistiocytosis.	MET
31819518	10.2147/OTT.S230309	2020	Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.	MET
31837735	10.1016/j.jcyt.2019.10.005	2020	Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.	MET
31861431	10.3390/nu12010007	2020	A Systematic Review of Organic Versus Conventional Food Consumption: Is There a Measurable Benefit on Human Health?	MET
31866457	10.1016/j.wneu.2019.12.063	2020	Outcomes and Costs Following Ommaya Placement with Thrombocytopenia Among U.S. Patients with Cancer.	MET
31867838	10.1002/pbc.28142	2020	Definition of cortical bone involvement in the staging of newly diagnosed pediatric Hodgkin lymphoma: A report from the International Working Group on Staging Evaluation and Response Criteria Harmonization (SEARCH).	MET
31869413	10.1182/bloodadvances.2019001016	2020	Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.	MET
31877085	10.1200/JCO.19.02407	2020	Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk.	MET
31916104	10.1007/s11547-019-01128-3	2020	Investigating dynamic susceptibility contrast-enhanced perfusion-weighted magnetic resonance imaging in posterior fossa tumors: differences and similarities with supratentorial tumors.	MET
31918382	10.1016/j.bcmd.2019.102393	2020	Coagulopathy in cytogenetically and molecularly distinct acute leukemias at diagnosis: Comprehensive study.	MET
31944221	10.1001/jamaoncol.2019.5868	2020	Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.	MET
31955214	10.1007/s00277-020-03908-8	2020	In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.	MET
31959992	10.1038/s41591-019-0737-3	2020	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.	MET
32035682	10.1016/j.transproceed.2019.12.011	2020	Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.	MET
32047535	10.1177/1758835919895756	2020	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.	MET
32063103	10.1177/1078155219900909	2020	Evaluation of mobilization efficacy with an extended interval following plerixafor administration.	MET
32064218	10.7759/cureus.6900	2020	Surface Dosimetry of Patients Undergoing Total Body Irradiation: A Retrospective Analysis for Quality Assurance.	MET
32089043	10.1177/1043454220907547	2020	A Literature Review of Racial Disparities in Overall Survival of Black Children With Acute Lymphoblastic Leukemia Compared With White Children With Acute Lymphoblastic Leukemia.	MET
32129443	10.1093/jjco/hyaa010	2020	Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma.	MET
32170769	10.1002/ajh.25783	2020	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.	MET
32183146	10.3390/molecules25061320	2020	Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.	MET
32184940	10.4254/wjh.v12.i2.34	2020	Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma.	MET
32200522	10.1007/s41669-020-00204-z	2020	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews.	MET
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	MET
32327174	10.1016/j.thorsurg.2020.01.004	2020	Molecular Targets Beyond the Big 3.	MET
32351825	10.7759/cureus.7446	2020	Steroid-induced Lactic Acidosis in Diffuse Large B-cell Lymphoma.	MET
32430062	10.1186/s12940-020-00582-1	2020	A systematic review and meta-analysis of haematological malignancies in residents living near petrochemical facilities.	MET
32447492	10.1007/s00428-020-02822-8	2020	Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.	MET
32628701	10.1371/journal.pone.0235328	2020	Aptamer based proteomic pilot study reveals a urine signature indicative of pediatric urinary tract infections.	MET
32714689	10.7759/cureus.8751	2020	A Retrospective Cohort and Systematic Review of Non-Operative Management of Exposed Calvaria Post-Radiotherapy.	MET
32758434	10.1016/S2352-3026(20)30208-8	2020	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.	MET
32762998	10.1016/j.jval.2020.04.1825	2020	EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review.	MET
32782583	10.3892/ol.2020.11842	2020	Extranodal NK/T-cell lymphoma, nasal type without evidence of EBV infection.	MET
32872120	10.3390/jpm10030107	2020	Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, <i>ALK</i>-Positive, <i>TP53</i>-Mutant NSCLC.	MET
32956128	10.1097/RLU.0000000000003303	2020	High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma.	MET
32957736	10.3390/cancers12092658	2020	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review.	MET
32988155	10.3760/cma.j.cn112152-20200323-00248	2020	[Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].	MET
33020647	10.1038/s41591-020-1081-3	2020	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.	MET
33024658	10.1016/j.jbo.2020.100315	2020	c-Met expression in renal cell carcinoma with bone metastases.	MET
33038027	10.1002/14651858.CD013399.pub2	2020	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.	MET
33050643	10.3390/cancers12102921	2020	Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients.	MET
33053439	10.1016/j.critrevonc.2020.103119	2020	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	MET
33086451	10.3760/cma.j.cn112137-20200210-00234	2020	[Diagnosis and treatment of gastric cancer with immediate double primary carcinoma].	MET
33091355	10.1016/S2352-3026(20)30277-5	2020	Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.	MET
33269250	10.12998/wjcc.v8.i21.5139	2020	Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.	MET
29135973	10.1038/leu.2017.299	2019	HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.	MET
30477470	10.1186/s12885-018-5078-y	2019	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.	MET
30995847	10.14735/amko201990	2019	Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.	MET
31001658	10.1007/s00277-019-03689-9	2019	Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.	MET
31045771	10.1097/MD.0000000000015329	2019	A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.	MET
31126528	10.1016/S2352-3026(19)30051-1	2019	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.	MET
31196495	10.1016/j.suronc.2019.03.001	2019	Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis.	MET
31262854	10.21873/anticanres.13476	2019	From 'Targeted Therapy' to Targeted Therapy.	MET
31286808	10.1080/0284186X.2019.1637538	2019	Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.	MET
31366830	10.1248/cpb.c19-00084	2019	Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy.	MET
31401883	10.1080/14756366.2019.1639694	2019	Identification of 1<i>H</i>-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors.	MET
31490916		2019	Cancer in the HIV/AIDS Population in Iowa, 1991-2015.	MET
31542900		2019	The Utility of 18F-fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Cutaneous B-Cell Lymphoma.	MET
27136744	10.1038/srep25369	2018	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.	MET
27262592	10.1016/j.oraloncology.2016.05.015	2018	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.	MET
28502721	10.1016/j.jtho.2017.04.031	2018	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.	MET
30037377	10.3779/j.issn.1009-3419.2018.07.09	2018	[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].	MET
27496196	10.1186/s13045-016-0296-8	2017	Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.	MET
27912827	10.1016/j.hoc.2016.08.010	2017	New Targets in Non-Small Cell Lung Cancer.	MET
28285687	10.1016/j.lungcan.2017.02.008	2017	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.	MET
28324883	10.1159/000457801	2017	MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma.	MET
28337527	10.1007/s00277-017-2980-3	2017	Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.	MET
25847631	10.1111/his.12709	2016	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.	MET
26581482	10.1186/s13104-015-1675-x	2016	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.	MET
24389444	10.1097/JTO.0b013e3182a00e37	2015	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.	MET
24722154	10.1097/JTO.0000000000000145	2015	High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.	MET
24835487	10.1038/ncomms4907	2015	Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways.	MET
25502629	10.3892/ijo.2014.2797	2015	Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.	MET
25916750	10.1111/iep.12128	2015	Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.	MET
23208509	10.1038/onc.2012.551	2014	Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.	MET
23558571	10.1038/modpathol.2013.64	2014	MET and MST1R as prognostic factors for classical Hodgkin's lymphoma.	MET
23745832	10.1111/cas.12215	2014	Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP.	MET
23919423	10.3109/01902148.2013.819535	2014	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.	MET
24200637	10.1016/j.cancergen.2013.09.004	2014	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.	MET
24212721	10.1245/s10434-013-3355-1	2014	MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.	MET
23335077	10.1002/ijc.28047	2013	Expression and clinical relevance of MET and ALK in Ewing sarcomas.	MET
23379953	10.1186/1746-1596-8-16	2013	High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma.	MET
23449277	10.1097/JTO.0b013e318287c395	2013	MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.	MET
23841470	10.1164/rccm.201305-0843PP	2013	The impact of genomic changes on treatment of lung cancer.	MET
22180430	10.3324/haematol.2011.056101	2012	Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.	MET
22198430	10.1097/JTO.0b013e318241655f	2012	c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.	MET
21623265	10.1097/JTO.0b013e31821528d3	2011	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	MET
18813782		2008	Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.	MET
17673463	10.1074/jbc.M706314200	2007	Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation.	MET
17702746	10.1074/jbc.M702573200	2007	CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.	MET
